

# 5-Hydroxytryptamine and Atrial Fibrillation: How Significant is This Piece in the Puzzle?

SHAMIL YUSUF, M.R.C.P., NAAB AL-SAADY, PH.D., and A. JOHN CAMM, M.D.

From the Department of Cardiovascular Medicine, The Medical School, St. Georges Hospital Medical School, London, United Kingdom

**Serotonin and Atrial Fibrillation.** 5-Hydroxytryptamine, a recent addition to the list of hormonal triggers for atrial fibrillation (AF), may play a pivotal role in the induction of AF related not only to cardiac surgery but also to acute coronary syndromes, valvular heart disease, cardiomyopathies, alcoholism, aging, and conducting tissue disease. This review examines the supporting laboratory and clinical evidence and provides a comprehensive insight into the basic underlying mechanisms involved. It also delves into the potential benefits and limitations of 5-HT<sub>4</sub> antagonists in the prevention and management of this arrhythmia. (*J Cardiovasc Electrophysiol*, Vol. 14, pp. 209-214, February 2003)

*atrial fibrillation, 5-hydroxytryptamine, arrhythmia*

## Introduction

The serendipitous observation that atrial fibrillation (AF) could be successfully treated was arguably made almost 300 years ago, when chincona bark was used to treat malaria and was also noted to correct irregular heartbeat.<sup>1</sup> This most common of arrhythmias currently affects an estimated 2.3 million Americans<sup>2</sup> and continues to be responsible for significant morbidity and mortality.<sup>3</sup> This is a reflection of the complex, heterogeneous, and challenging nature of AF. In humans, the atria are subject to numerous different insults, and the final endpoint is AF. Furthermore, the longer this arrhythmia is present, the more resilient it is to reversal due to anatomic, electrical, and histologic remodeling.<sup>4-6</sup> The multiple factors involved in the pathogenesis of AF act either independently or in concert, and a recent addition to this list of factors is 5-hydroxytryptamine (5-HT; serotonin). As early as the 1950s, infusion of 5-HT into humans was known to produce a myriad of unpredictable cardiovascular responses.<sup>7,8</sup> A sinus tachycardia was consistently induced, and bizarre atrial arrhythmias occasionally were triggered. Over the last decade, significant advances have been made in deciphering and understanding serotonergic mechanisms, not only in the cardiovascular system but also in the central nervous system and gastrointestinal tract. This review concentrates on the serotonergic regulation of the human atria, exploring the chronotropic, inotropic, and lusitropic effects; the basic mechanisms underlying these actions; and a possible explanation for the existence of such a system in humans. The review explains how this system may be more of a hindrance than a benefit, especially in the generation of atrial arrhythmias, particularly AF. It also provides a brief overall view of the role of 5-HT in the regulation of the cardiovascular system as a whole.

## Serotonin, Serotonergic Receptors, the Cardiovascular System, and the Human Atria

Serotonin is a fast-acting, small-molecule, indoleamine neurotransmitter that is produced and secreted by serotonergic neurons in the central and enteric nervous systems in humans. It is synthesized by the hydroxylation of the amino acid tryptophan by tryptophan hydroxylase to 5-hydroxytryptophan, which is decarboxylated to 5-HT by aromatic amino acid decarboxylase. Following synthesis, 5-HT is stored in small vesicles in nerve terminals prior to being released. Once released, 5-HT is metabolized by monoamine oxidase (MAO) present in the intestine, liver, and mitochondria in the cytoplasm of serotonergic neurons. 5-HT is also taken up by circulating blood platelets; thus, although platelets do not synthesize 5-HT, they can store and release 5-HT when activated.

Over the last several years, molecular cloning techniques have revealed a vast diversity among 5-HT receptors. These receptors are classified according to their *structural* (primary amino acid sequence), *transductional* (second messenger coupling), and *operational* or *recognitory* (pharmacologic) characteristics.<sup>9,10</sup> Seven distinct serotonergic receptor classes have been recognized (5-HT<sub>1</sub> to 5-HT<sub>7</sub>), each encoded by a separate gene. Furthermore, the 5-HT<sub>1</sub>, 5-HT<sub>2</sub>, 5-HT<sub>4</sub>, and 5-HT<sub>5</sub> classes currently consist of five (5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, 5-HT<sub>1D</sub>, 5-HT<sub>1E</sub>, 5-HT<sub>1F</sub>), three (5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, 5-HT<sub>2C</sub>), four (5-HT<sub>4A</sub>, 5-HT<sub>4B</sub>, 5-HT<sub>4C</sub>, 5-HT<sub>4D</sub>), and two (5-HT<sub>5A</sub>, 5-HT<sub>5B</sub>) subclasses, respectively. The 5-HT<sub>1C</sub> subclass has been reclassified as the 5-HT<sub>2C</sub> subtype.<sup>9</sup> Some of these subclasses are themselves encoded by separate genes, others by variable expression of exon lengths leading to splice variants (e.g., 5-HT<sub>4</sub><sup>11</sup> and 5-HT<sub>7</sub><sup>12</sup>). All but one 5-HT receptor subclass, namely, 5-HT<sub>3</sub>, belong to the G-protein coupled or seven transmembrane-spanning receptor family.<sup>10</sup> 5-HT<sub>3</sub> receptors are directly coupled to ligand-gated cation channels. It is noteworthy that the existence of receptor (sub)types 5-HT<sub>1E/1F</sub>, 5-HT<sub>5A/B</sub>, 5-HT<sub>6</sub>, and 5-HT<sub>7</sub> has been generated from molecular biologic techniques, and there are no known agonists/antagonists for them. As such, their functional responses, except coupling to adenylyl cyclase, have yet to be elucidated.<sup>9</sup> Furthermore and more importantly, different 5-HT receptor subtypes are responsible for similar effector responses across the species barrier. Hence, extreme caution

Address for correspondence: Shamil Yusuf, M.R.C.P., Department of Cardiological Sciences, The Medical School, St. Georges Hospital, Cranmer Terrace, London SW 17 0RE, United Kingdom. E-mail: syusuf@sghms.ac.uk

Manuscript received 26 August 2002; Accepted for publication 23 October 2002.

must be exercised when extrapolating the operational characteristics derived from other animal species to humans.


Serotonergic regulation of the cardiovascular system as a whole is complex. It involves both central and peripheral mechanisms acting through the numerous receptor subtypes. Centrally mediated mechanisms involve the regulation of autonomic tracts in the brainstem and midbrain by serotonergic neurons originating in the higher centers. Serotonergic neurons located in the raphe obscurus and raphe pallidus project to the autonomic areas of the lower brainstem and spinal cord, whereas forebrain areas involved in cardiovascular regulation receive their serotonergic input from the dorsal raphe.<sup>13-15</sup> This central regulation of the cardiovascular system is executed predominantly through 5-HT<sub>1A</sub> (sympathoinhibitory and vagal bradycardia) and 5-HT<sub>2</sub> (sympathoexcitatory) receptor subtypes.<sup>16</sup> Stimulation of 5-HT<sub>1A</sub> receptors produces a vasopressor and bradycardic effect, which results from a combination of central sympathetic activity inhibition and central stimulation of the vagus nerve. On the other hand, stimulation of central 5-HT<sub>2</sub> receptors results in vasoconstriction and tachycardia due to increased sympathetic discharge.

Peripherally, numerous serotonergic receptors and receptor subtypes modulate a range of cardiovascular functions, including vasoconstriction, vasodilation, platelet aggregation, and positive inotropic, lusitropic, and chronotropic effects. The receptor subtype 5-HT<sub>1D</sub> has been implicated in vasoconstriction, and its agonist sumatriptan is used in the prevention and treatment of migraine. 5-HT<sub>1D</sub> receptors have also been identified in human coronary vessels,<sup>17</sup> especially those affected by atheroma,<sup>18,19</sup> and they likely play a significant role in angina; hence, 5-HT<sub>1D</sub> receptor agonists such as sumatriptan are contraindicated in patients with atheromatous coronary artery disease. The 5-HT<sub>2A</sub> receptor antagonist ketanserin offered great promise for the treatment of hypertension,<sup>20</sup> but despite its effectiveness at lowering blood pressure it was withdrawn due to its propensity to proarrhythmia. Whether ketanserin's effect of lowering blood pressure is due to its effects on the 5-HT<sub>2</sub> receptor has always been debatable. Ketanserin also has  $\alpha_1$ -adrenoreceptor blocking properties, central sympathoinhibitory properties, and direct vasodilatory properties.<sup>21</sup> No other selective 5-HT<sub>2</sub> receptor antagonist (e.g., ritanserin and mianserin) effectively lowers blood pressure.<sup>21</sup> On the other hand, 5-HT<sub>2</sub> receptors play an important role in 5-HT reuptake and platelet aggregation. 5-HT<sub>3</sub> receptors require a special mention, because these unique ligand-gated cation channel receptors are present on human afferent vagal nerve endings and are responsible for the von Bezold-Jarisch reflex in humans.<sup>22</sup> This consists of an initial hypotensive response to 5-HT, an effect that results from an abrupt and transient bradycardia (and the consequent decrease in cardiac output) following stimulation of 5-HT<sub>3</sub> receptors on afferent cardiac vagal nerve endings.

In humans, positive inotropic, chronotropic, and lusitropic effects on the atrial myocardium are mediated through 5-HT<sub>4</sub> receptors. The presence of a 5-HT receptor within the human right atrium was first demonstrated in 1989.<sup>23</sup> Subsequent studies on similar right atrial appendage tissue, excised during coronary artery bypass surgery, revealed that this receptor bears a marked resemblance to the rodent cerebral 5-HT<sub>4</sub> receptor.<sup>24</sup> Furthermore, 5-HT<sub>4</sub> receptors with characteristics similar to those in the right atrium were found in the left atria of patients with terminal heart failure.<sup>25</sup> The exact na-

ture of human sinoatrial 5-HT receptors through which the tachycardia response is mediated is still unknown; however, ample evidence suggests that it is highly likely they are also 5-HT<sub>4</sub> in nature.<sup>26</sup> First, in the porcine model, 5-HT induces a tachycardia through receptors that are very similar to human atrial 5-HT<sub>4</sub> receptors.<sup>27</sup> Second, in isolated piglet sinoatrial tissue<sup>28,29</sup> and human atria,<sup>24</sup> 5-HT<sub>4</sub> receptors have the same order of potency for agonists and a similar order of antagonist affinity.<sup>28-30</sup> Finally, cisapride, which is a partial 5-HT<sub>4</sub> receptor agonist for both porcine sinoatrial node<sup>28</sup> and human right atrium,<sup>24</sup> can also cause sinus tachycardia in humans, presumably through this mechanism.<sup>31-33</sup>

Like the majority of other 5-HT receptors, 5-HT<sub>4</sub> receptors in human atrial tissue are coupled to G<sub>s</sub> proteins, and stimulation causes an increase in contractile force and accelerates the onset of muscle relaxation via increased cyclic adenosine monophosphate (cAMP) levels and cAMP-dependent protein kinase A (PKA) activity<sup>34</sup> (Fig. 1). Patch clamp atrial myocyte experiments have demonstrated that this increased contractile force is a result of phosphorylation of membrane-bound and sarcolemmal L-type Ca<sup>2+</sup> channels (i<sub>CaL</sub>) by PKA leading to increased atrial cytoplasmic ionized calcium.<sup>35</sup> The role of PKA is obligatory in this process.<sup>35</sup> The hastened onset of atrial relaxation produced by 5-HT has been attributed to PK-dependent phosphorylation of phospholamban



**Figure 1.** Physiology of 5HT<sub>4</sub> receptor stimulation in cardiac myocytes and its possible role in the generation of atrial arrhythmias. Alternate splicing results in expression of three variants of the 5HT<sub>4</sub> receptor: 5HT<sub>4a</sub>, 5HT<sub>4b</sub>, and 5HT<sub>4c</sub>. Although 5HT<sub>4a</sub> and 5HT<sub>4b</sub> isoforms require agonist stimulation, it appears that 5HT<sub>4c</sub> demonstrates basal constitutive activation to cause a rise in the level of cAMP. cAMP in turn stimulates hyperpolarization-activated "funny" currents (i<sub>f</sub>), and protein kinase A activity. Protein kinase A leads to phosphorylation of both L-type Ca<sup>2+</sup> channels (i<sub>CaL</sub>) leading to increased cytoplasmic ionized Ca<sup>2+</sup> and phospholamban, which hastens the onset of atrial relaxation by the resultant acceleration of Ca<sup>2+</sup> capture by the sarcoplasmic reticulum and/or desensitization of the contractile proteins to Ca<sup>2+</sup>.

and/or troponin I, followed by the resultant acceleration of calcium capture by the sarcoplasmic reticulum and/or desensitization of the contractile proteins to  $\text{Ca}^{2+}$ .<sup>34</sup>

Until recently, one exciting observation had been that 5-HT<sub>4</sub> mRNA had not been detected in human ventricular tissue.<sup>36,37</sup> This implied that any 5-HT<sub>4</sub> receptor antagonists developed would be atrium specific and free of ventricular proarrhythmia. However, Bach et al.<sup>38</sup> have demonstrated that 5-HT<sub>4</sub> mRNA is detectable in human ventricular tissue acquired from two patients. Nonetheless, this does not explain why 5-HT did not modify the L-type  $\text{Ca}^{2+}$  ( $i_{\text{CaL}}$ ) current in human ventricular myocytes or cause positive inotropic effects in ventricular trabeculae when investigated by Jahnel et al.<sup>39</sup> Furthermore, there is no record of 5-HT infusions or any experimental 5-HT agonist ever inducing ventricular arrhythmias. Thus, the mere presence of mRNA does not automatically imply translation and expression through a protein product. In addition, gene expression is subject to activation/deactivation depending on genetic predisposition and environmental factors. Clearly, the role of human ventricular 5-HT<sub>4</sub> mRNA requires further investigation.

Finally, following 5-HT<sub>4</sub> receptor stimulation, desensitization of the atrial myocardium occurs to a lesser extent than that reported at other 5-HT<sub>4</sub> receptor sites.<sup>40</sup> Differences in the potential phosphorylation sites in the sequences of the 5-HT<sub>4</sub> receptor isoforms may account for this finding.<sup>11</sup>

### 5-HT<sub>4</sub> Receptors and AF

Theoretically, 5-HT-induced cardiac arrhythmias, particularly AF, can be initiated not only through stimulation of 5-HT receptors peripherally but also through central serotonergic mechanisms. However, at present there is very little direct evidence that the central serotonergic neuronal input upon the autonomic nervous system and its sympathoinhibitory/sympathoexcitatory and provagal influences are involved in the generation of cardiac arrhythmias. In addition, most of the observations of the effects of central serotonergic neurons are based upon a variety of different animal species, and extrapolating these findings to humans should be undertaken with caution.

Peripherally, cardiac arrhythmias can be generated by stimulation of 5-HT<sub>3</sub> receptors on vagal afferents<sup>41</sup> and atrial arrhythmias by stimulation of 5-HT<sub>4</sub> receptors on atrial myocytes.<sup>40,42</sup> Ventricular arrhythmias have been reported secondary to administration of ketanserin, which is a well-known antagonist of the rapid component of the delayed rectifier  $\text{K}^+$  current ( $i_{\text{Kr}}$ ) that prolongs QT,<sup>43-45</sup> but as mentioned earlier it is also a 5-HT<sub>2</sub> receptor antagonist.<sup>46</sup> There is some evidence that 5-HT<sub>2</sub> receptors play little or no role in ventricular arrhythmias generated by ketanserin.<sup>47</sup>

The mere existence of 5-HT<sub>4</sub> receptors in the human atria begs the teleologic question as to why they exist. It appears that like many other systems in the human body, these receptors may represent a hormonal backup mechanism for dysfunction of the intracardiac conducting system and/or its autonomic influences. Dysfunction of either of these systems invariably generates various bradyarrhythmias leading to hemostasis, platelet activation, and aggregation. In the human cardiovascular system, 5-HT is released from the *dense granules* in activated platelets contributing to vasoconstriction and platelet aggregation as part of the normal physiologic hemostatic process. Platelets activated within the hu-

man atria in response to bradyarrhythmias would have positive inotropic, chronotropic, and lusitropic effects by stimulating 5-HT<sub>4</sub> receptors. How much protection this system offers asymptomatic patients with conducting tissue disease is unknown. There is little doubt, however, that this system could be more of a hindrance than a benefit. There is in vivo, in vitro, and clinical evidence that stimulation of 5-HT<sub>4</sub> receptors, in addition to causing sinus tachycardia, can trigger atrial arrhythmias including AF.

First, in the early 1950s, direct infusion of 5-HT into humans was noted to trigger bizarre atrial arrhythmias.<sup>7,8</sup> Second, in isolated human atrial tissue, 5-HT has been shown to induce rate-dependent arrhythmic contractions through 5-HT<sub>4</sub> receptors, particularly in tissue that has been subjected to chronic  $\beta$ -adrenoreceptor blockade.<sup>42</sup> Third, using rapid atrial pacing to induce atrial flutter and fibrillation in pigs, Rahme et al.<sup>48</sup> demonstrated that the 5-HT<sub>4</sub> antagonist RS-100302 terminated atrial fibrillation/flutter in the majority of cases and prevented reinduction of sustained tachycardia in all animals. Fourth, the partial 5-HT<sub>4</sub> receptor agonist cisapride, in addition to inducing sinus tachycardias as mentioned earlier, has been reported to induce other supraventricular tachycardias in humans.<sup>32,33</sup> It is noteworthy, however, that cisapride is also a known antagonist of the rapidly activating delayed rectifier  $\text{K}^+$  current ( $i_{\text{Kr}}$ ) and well documented to be responsible for QT prolongation and ventricular arrhythmias.<sup>49,50</sup> Finally, the clinical association between AF and advancing age, hypertension, ischemic heart disease, valvular heart disease, cardiomyopathies, and coronary artery bypass grafting is well established.<sup>3</sup> In all of these conditions except one, there is an abundance of evidence demonstrating that both platelet handling and metabolism of 5-HT are altered. With advancing age, not only is 5-HT uptake by platelets more rigorous<sup>51</sup> and platelet 5-HT levels higher,<sup>52,53</sup> but platelet sensitivity to 5-HT and hence their tendency to degranulate also are increased.<sup>52,54</sup> In hypertensive patients, on the other hand, platelet 5-HT levels are decreased<sup>55-59</sup> due to a combination of increased release from,<sup>55,59</sup> and reduced uptake by, platelets.<sup>57,59</sup> Consequently, plasma serotonin levels in hypertensive patients are higher compared with normotensive controls.<sup>55,59</sup> In valvular heart disease, sheer stress leads to platelet activation<sup>60,61</sup> and undoubtedly an increase in plasma 5-HT levels. Similarly, in cardiomyopathies, stasis and turbulence lead to platelet aggregation and would be expected to increase platelet 5-HT release and plasma 5-HT levels, although this has not been formally demonstrated in any study. In acute coronary syndromes, there is platelet activation and increased 5-HT levels across the coronary vascular bed.<sup>62</sup> A pathogenic role for 5-HT has been implicated in vasospastic angina.<sup>63</sup> About 30% of all patients undergoing coronary artery bypass grafting develop AF, usually within 5 days of the procedure.<sup>64,65</sup> This is a much higher proportion than can be accounted for by existing underlying ischemic heart disease, hypertension, or left ventricular dysfunction. The exact reasons for this finding are unknown.<sup>64</sup> It is possible that platelet activation and release of 5-HT play the crucial role. Even in alcohol dependency, where the association with AF is well established, there is deranged storage and 5-HT handling by platelets.<sup>66</sup> Furthermore, diurnal variations in paroxysmal AF are well documented<sup>67</sup> and previously have been attributed to circadian variation in autonomic activity<sup>68</sup>; however, 5-HT also may be implicated. Not only does platelet aggregation exhibit diurnal variation,<sup>69</sup> but so do

platelet 5-HT uptake and platelet 5-HT levels.<sup>70</sup> It has been postulated that the influence of melatonin upon the 5-HT uptake mechanism is responsible for this phenomenon.<sup>71</sup>

The case for 5-HT in the pathogenesis of AF across a whole range of different laboratory-based and clinical conditions is overwhelming. However, experience with a low incidence of AF in carcinoid syndrome indicates that elevated plasma levels of 5-HT is only half the story. The other part is the atrial myocardium and expression of 5-HT<sub>4</sub> receptors, not just as a whole, but also of its various subtypes and their affinities to 5-HT under different clinical conditions. However, apart from the observations that up to four different 5-HT<sub>4</sub> receptor isoforms may be expressed in human atrial tissue,<sup>37</sup> little information is available on the effects of aging and various other clinical conditions on their expressions and affinities.

The underlying mechanisms involved in 5-HT-mediated AF are similar to other hormonal triggers of AF, namely, catecholamine or excess thyroxine induced.<sup>72</sup> Two processes have been proposed in attempt to explain the electrophysiopathologic basis of any form of AF. First, from the observation that AF often is initiated or preceded by an atrial extrasystole as determined by ECG evidence, the *focal mechanism theory* proposes that enhanced automaticity in one or more rapidly depolarizing foci within the atria are responsible for AF. Histologically, cardiac muscle cells with preserved electrical properties extend into the pulmonary veins, the predominant site for such enhanced focal automaticity.<sup>73,74</sup> Foci of enhanced automaticity also occur in the right atrium and infrequently in the superior vena cava or coronary sinus.<sup>73-75</sup> Numerous factors such as autonomic nervous system activity, atrial ischemia, atrial stretch, anisotropic conduction, aging, and fibrosis can be responsible for the generation of such automatic foci.

The second *reentrant circuit theory* of AF proposes that the existence of one or more reentrant circuits within the atria are responsible for AF.<sup>76,77</sup> Moe et al.<sup>76,77</sup> proposed that wavefronts of electrical activity fractionate as they propagate through the atria and result in self-perpetuating "daughter wavelets." An increase in the number of these daughter wavelets increases the propensity for continuation of AF. The number of these daughter wavelets is influenced by (1) shortening of atrial effective refractory period (ERP) and increased dispersion of the ERP (ERP<sub>DISP</sub>)<sup>4,78-80</sup>; (2) decrease in conduction velocity<sup>79,81</sup>; and (3) increased atrial size or mass.<sup>79,81</sup>

The 5-HT<sub>4</sub> receptor stimulation in the human atria may trigger focal atrial extrasystoles by calcium overload leading to induction of AF. Various studies have demonstrated that overloading cardiac myocytes with Ca<sup>2+</sup> can be associated with the generation of arrhythmias,<sup>82,83</sup> which are thought to be due to generation of Ca<sup>2+</sup>-dependent delayed afterdepolarizations resulting in triggered action potentials.<sup>84</sup> Pino et al.<sup>85</sup> also demonstrated that 5-HT<sub>4</sub> receptor stimulation increases the pacemaker (I<sub>f</sub>) current in human atrial myocytes via the cAMP pathway. This effect can lead to shortening of atrial ERP and increased dispersion of atrial ERP, which might be responsible for the arrhythmogenic potential of 5-HT in the human atrium. Finally, the effect of 5-HT<sub>4</sub> receptor stimulation on the inward *ultrarapid* component of the delayed rectifier K<sup>+</sup> current (I<sub>Kur</sub>) is unknown. These channels are specific to the human atria and are under strong adrenergic influence.<sup>86,87</sup> As such, they are likely to be affected by sero-

tonin producing atrial-specific effects including arrhythmias, which may be inhibited by potential 5-HT<sub>4</sub> antagonists.

Once initiated by whatever mechanism (5-HT related or another), AF also may be maintained by 5-HT. Ample evidence exists that AF leads to platelet activation.<sup>88,89</sup> This is a result of irregular atrial wall motion,<sup>90</sup> endothelial damage,<sup>91</sup> and/or reduced plasma adenosine levels<sup>92</sup> seen in AF. This leads to 5-HT release and stimulation of 5-HT<sub>4</sub> receptors in the atria, potentially perpetuating the fibrillation. However, the altered expression of the various 5-HT<sub>4</sub> receptor isoforms could be pivotal in this process. Blondel et al. demonstrated that the human 5-HT<sub>4</sub> receptor subtype (c) exhibits basal constitutive activation of adenylyl cyclase resulting in an increased basal cAMP level<sup>37</sup>. Furthermore human 5-HT<sub>4</sub> receptor isoforms (a) and (b) express similar basal constitutive activation of adenylyl cyclase when over expressed<sup>37</sup>.

The discovery of 5-HT<sub>4</sub> receptors in the human atria and their possible role in arrhythmia generation has led to the development of a number of 5-HT<sub>4</sub> receptor antagonists.<sup>93</sup> Theoretically, such agents could influence management in all cases of atrial arrhythmias where the onset is associated with platelet activation, including acute coronary syndromes, conducting tissue disease, cardiomyopathies, and valvular heart disease. However, the presence of a number of other contributing variables in these conditions, such as hyperadrenergic drive and electrical/histologic remodeling of the atria, means that the overall therapeutic benefit of 5-HT<sub>4</sub> receptor antagonists in these settings is likely to be minimal. The biggest impact of these agents probably will be in the prevention and management of postoperative AF, particularly after cardiac surgery. Use of these agents would eliminate undesirable side effects such as negative inotropism and chronotropism associated with other antiarrhythmic drugs used in this setting. 5-HT<sub>4</sub> receptor antagonists may prove to be a welcome addition to our current arsenal of antiarrhythmic drugs, especially if the risk of ventricular proarrhythmia is confirmed to be negligible.

The excitement surrounding the potential benefits of 5-HT<sub>4</sub> receptor antagonists has been to the detriment of 5-HT<sub>4</sub> receptor agonists. Such agents have the potential to be effective not only in symptomatic sinus bradycardias and certain conducting tissue diseases but also in the clinical minefield of autonomic dysfunction and vasovagal syncope. However, the proarrhythmic potential of such agents through their effects on the *funny* (I<sub>f</sub>) current, the L-type calcium current (I<sub>CaL</sub>), and their potential effect on the inward *ultrarapid* component of the delayed rectifier K<sup>+</sup> current (I<sub>Kur</sub>) means they are unlikely to become available for clinical use in the short to medium term. Nevertheless, such compounds still can provide invaluable information about the distribution, functions, and affinities of the different 5-HT<sub>4</sub> receptor subtypes.

## Conclusion

The account of the role of 5-HT in the initiation and maintenance of AF outlined here provides a most plausible development to our understanding of the causes of AF; however, a number of important questions remain unanswered. First, what the exact distribution of 5-HT<sub>4</sub> receptors across the entire human myocardium? Second, what is the exact nature of these 5-HT<sub>4</sub> receptor subtypes, and what impact does aging and other factors predisposing to AF have on their expression and affinities? Third, what effect, if any, do the changes in

5-HT<sub>4</sub> receptor and/or isotype expression have on anatomic, electrical, and ionic remodeling? Finally, like all the other contributing factors to AF, what is it about the atrium that renders certain individuals susceptible to the influence of 5-HT? This account highlights that not all the underlying mechanisms responsible for AF have been resolved. Furthermore, for every possible contributing factor, a thorough understanding of the basic science is essential for maximal clinical impact. The war against AF may be 300 years old, but there appears to be no shortage of new battlefronts over which to try and make a real impact. With an ever-aging population in the West and the prediction that the prevalence of AF is likely to increase 2.5-fold in the next 50 years,<sup>2</sup> such that between 5.0 and 6.3 million Americans will likely be affected by 2050, no effort should be spared in the attempt to win this war.

## References

- Prinz A: Zur Entdeckung der Herzwirksamkeit der Chinarinde und ihrer Alkaloide. *Wein Klin Wochenschr* 1990;102:721-723.
- Go A, Hylek E, Phillips K, Chang Y, Henault L, Selby J, Singer D: Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *JAMA* 2001;285:2370-2375.
- Wolf P, Dawber T, Thomas HJ, Kannel W: Epidemiological assessment of chronic atrial fibrillation and the risk of stroke. The Framingham Study. *Neurology* 1978;1978:973-977.
- Wijffels M, Kirchhof C, Dorland R, Allesie M: Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats. *Circulation* 1995;92:1954-1968.
- Li D, Fareh S, Leung TK, Nattel S: Promotion of atrial fibrillation by heart failure in dogs: Atrial remodeling of a different sort. *Circulation* 1999;100:87-95.
- Li D, Melnyk P, Feng J, Wang Z, Petrecca K, Shrier A, Nattel S: Effects of experimental heart failure on atrial cellular and ionic electrophysiology. *Circulation* 2000;101:2631-2638.
- Hollander W, Michelson AL, Wilkins RW: Serotonin and antiserotonins, 1. Their circulatory, renal and respiratory effects in man. *Circulation* 1957;16:246-255.
- LeMessurier DH, Schwartz CJ, Whelan RF: Cardiovascular effects of intravenous infusions of 5-hydroxytryptamine in man. *Br J Pharmacol* 1959;14:246-250.
- Humphrey PP, Hartig P, Hoyer D: A proposed new nomenclature for 5-HT receptors. *Trends Pharmacol Sci* 1993;14:233-236.
- Hoyer D, Martin G: 5HT receptor classification and nomenclature: Towards harmonisation with the human genome. *Neuropharmacology* 1997;36:418-428.
- Gerald C, Adham N, Kao HT, Olsen MA, Laz TM, Schechter LE, Bard JA, Vaysse PJ, Hartig PR, Branchek TA: The 5-HT<sub>4</sub> receptor: Molecular cloning and pharmacological characterization of two splice variants. *EMBO J* 1995;14:2806-2815.
- Heidmann D, Metcalf M, Kohen R, Hamblin M: Four 5 hydroxytryptamine 7 (5HT<sub>7</sub>) receptor isoforms in human and rat produced by alternative splicing: species differences due to altered intron-exon organisation. *J Neurochem* 1997;68:1372-1381.
- Fuxe K: Evidence for the existence of monoamine neurones in the CVS. IV. The distribution of monoamine terminals in the CNS. *Acta Physiol Scand* 1965;64:38-85.
- Bobillier P, Sequin S, Petitjean F, Salvart D, Tourset M, Jouvet M: The raphe nuclei of the cat brain stem: A topographical atlas of their efferent projections as revealed by autoradiography. *Brain Res* 1976;113:449-486.
- Jacobs B, Gannon P, Azmita E: Atlas of serotonergic cell bodies in the cat brainstem: An immunocytochemical analysis. *Brain Res Bull* 1984;13:1-31.
- McCall R, Clement M: Role of serotonin 1a and serotonin 2 receptors in the central regulation of the cardiovascular system. *Pharmacol Rev* 1994;46:231-243.
- Kaumann AJ, Frenken M, Posival H, Brown AM: Variable participation of 5-HT<sub>1</sub>-like receptors and 5-HT<sub>2</sub> receptors in serotonin-induced contraction of human isolated coronary arteries. 5-HT<sub>1</sub>-like receptors resemble cloned 5-HT<sub>1D</sub> beta receptors. *Circulation* 1994;90:1141-1153.
- Berkenboom G, Unger P, Fang ZY, Degre S, Fontaine J: Comparison of responses to acetylcholine and serotonin on isolated canine and human coronary arteries. *Cardiovasc Res* 1989;23:780-787.
- Toda N, Okamura T: Comparison of the response to 5-carboxamidotryptamine and serotonin in isolated human, monkey and dog coronary arteries. *J Pharmacol Exp Ther* 1990;253:676-682.
- Vanhoutte P, Amery A, Birkenhager W, Breckenridge A, Buhler F, Distler A, Dormandy J, Doyle A, Frohlich E, Hansson L: Serotonergic mechanisms in hypertension. Focus on the effects of ketanserin. *Hypertension* 1988;11:111-133.
- Saxena PR, Villalon CM: Cardiovascular effects of serotonin agonists and antagonists. *J Cardiovasc Pharmacol* 1990;15:S17-S34.
- Richardson BP, Engel G, Donatsch P, Stadler PA: Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. *Nature* 1985;316:126-131.
- Kaumann A, Sanders L, Brown A, Murray K, Brown M: A receptor for 5-hydroxytryptamine in human atrium. *B J Pharmacol* 1989;98:664P.
- Kaumann AJ, Sanders L, Brown AM, Murray KJ, Brown MJ: A 5-HT<sub>4</sub>-like receptor in human right atrium. *Naunyn Schmiedebergs Arch Pharmacol* 1991;344:150-159.
- Sanders L, Kaumann AJ: A 5-HT<sub>4</sub>-like receptor in human left atrium. *Naunyn Schmiedebergs Arch Pharmacol* 1992;345:382-386.
- Kaumann A: Do human atrial 5HT<sub>4</sub> receptors mediate arrhythmias? *Trends Pharmacol Sci* 1994;15:451-455.
- Parker S, Hamburger S, Taylor E, Kaumann A: SB203186, a potent 5HT<sub>4</sub> receptor antagonist in porcine sinoatrial node and human and porcine atrium. *Br J Pharmacol* 1993;108:68P.
- Kaumann AJ: Piglet sinoatrial 5-HT receptors resemble human atrial 5-HT<sub>4</sub>-like receptors. *Naunyn Schmiedebergs Arch Pharmacol* 1990;342:619-622.
- Medhurst A, Kaumann A: Characterization of the 5-HT<sub>4</sub> receptor mediating tachycardia in piglet isolated right atrium. *Br J Pharmacol* 1993;110:1023-1030.
- Brown A, Young T, Patch T, Cheung C, Kaumann A, Gaster L, King F: [<sup>125</sup>I]-SB 207710, a potent selective radioligand for 5HT<sub>4</sub> receptors. *Br J Pharmacol* 1993;110:9P.
- Bateman D: The action of cisapride on gastric emptying and the pharmacodynamics and pharmacokinetics of oral diazepam. *Eur Clin Pharmacol* 1986;30:205-208.
- Olsson S, Edwards IR: Tachycardia during cisapride treatment. *BMJ* 1992;305:748-749.
- Inman W, Kubota K: Tachycardia during cisapride treatment. *BMJ* 1992;305:1019.
- Kaumann A, Sanders L, Brown A, Murray K, Brown M: 5-Hydroxytryptamine receptor in the human atria. *Br J Pharmacol* 1990;100:879-885.
- Ouadid H, Seguin J, Dumuis A, Bockaert J, Nargeot J: Serotonin increases calcium current in human atrial myocytes via the newly described 5-hydroxytryptamine 4 receptors. *Mol Pharmacol* 1992;41:346-351.
- Blondel O, Vandecasteele G, Gastineau M, Leclerc S, Dahmoune Y, Langlois M, Fischmeister R: Molecular and functional characterisation of a 5HT<sub>4</sub> receptor cloned from human atrium. *FEBS Lett* 1997;412:465-474.
- Blondel O, Gastineau M, Dahmoune Y, Langlois M, Fischmeister R: Cloning expression and pharmacology of four human 5HT<sub>4</sub> receptor isoforms produced by alternative splicing in the carboxyl terminus. *J Neurochem* 1998;70:2252-2261.
- Bach T, Syverseen T, Kvingedal A, Krobert K, Brattelid T, Kaumann A, Levy F: 5HT<sub>4</sub>(a) and 5HT<sub>4</sub>(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle. *Naunyn Schmiedebergs Arch Pharmacol* 2001;363:146-160.
- Jahnel U, Rupp J, Ertl R, Nawrath H: Positive inotropic response to 5-HT in human atrial but not in ventricular heart muscle. *Naunyn Schmiedebergs Arch Pharmacol* 1992;346:482-485.
- Kaumann AJ, Gaster LM, King FD, Brown AM: Blockade of human atrial 5-HT<sub>4</sub> receptors by SB 207710, a selective and high affinity 5-HT<sub>4</sub> receptor antagonist. *Naunyn Schmiedebergs Arch Pharmacol* 1994;349:546-548.
- Saxena PR, Villalon CM: 5-Hydroxytryptamine: A chameleon in the heart. *Trends Pharmacol Sci* 1991;12:223-227.
- Kaumann AJ, Sanders L: 5-Hydroxytryptamine causes rate-dependent arrhythmias through 5-HT<sub>4</sub> receptors in human atrium: Facilitation by chronic beta-adrenoceptor blockade. *Naunyn Schmiedebergs Arch Pharmacol* 1994;349:331-337.
- Cameron HA, Waller PC, Ramsay LE: Prolongation of the QT interval by ketanserin. *Postgrad Med J* 1988;64:112-117.

44. Kaye GC, Mehta D, Wafa S, Camm AJ: Acute electrophysiologic effects of an HT<sub>2</sub>-serotonin antagonist, ketanserin, in humans. *Cardiovasc Drugs Ther* 1990;4:1157-60.
45. Zehender M, Meinerz T, Hohnloser S, Geibel A, Hartung J, Seiler KU, Just H: Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin. *Am J Cardiol* 1989;63:826-832.
46. Symoens J: Ketanserin: A novel cardiovascular drug. *Blood Coagul Fibrinolysis* 1990;1:219-224.
47. Le Grand B, Talmant JM, Rieu JP, Patoiseau JF, Colpaert FC, John GW: Investigation of the mechanism by which ketanserin prolongs the duration of the cardiac action potential. *J Cardiovasc Pharmacol* 1995;26:803-809.
48. Rahme M, Cotter B, Leistad E, Wadhwa M, Mohabir R, Ford A, Eglen R, Feld G: Electrophysiological and antiarrhythmic effects of atrial selective 5HT<sub>4</sub> receptor antagonist RS-100302 in experimental flutter and fibrillation. *Circulation* 1999;100:2010-2017.
49. Mohammad S, Zhou Z, Gong Q, January CT: Blockage of the HERG human cardiac K<sup>+</sup> channel by the gastrointestinal prokinetic agent cisapride. *Am J Physiol* 1997;273:H2534-H2538.
50. Rampe D, Roy ML, Dennis A, Brown AM: A mechanism for the proarrhythmic effects of cisapride (Propulsid): High affinity blockade of the human cardiac potassium channel HERG. *FEBS Lett* 1997;417:28-32.
51. Marazziti D, Falcone MF, Rotondo A, Castrogiovanni P: Age-related differences in human platelet 5-HT uptake. *Naunyn Schmiedeberg Arch Pharmacol* 1989;340:593-594.
52. Fetkovska N, Amstein R, Ferracin F, Regenass M, Buhler FR, Pletscher A: 5HT-kinetics and sensitivity of human blood platelets: Variations with age, gender and platelet number. *Thromb Haemost* 1988;60:486-490.
53. Kumar AM, Weiss S, Fernandez JB, Cruess D, Eisdorfer C: Peripheral serotonin levels in women: Role of aging and ethnicity. *Gerontology* 1998;44:211-216.
54. Gleerup G, Winther K: The effect of ageing on human platelet sensitivity to serotonin. *Eur J Clin Invest* 1988;18:504-506.
55. Biondi ML, Agostoni A, Marasini B: Serotonin levels in hypertension. *J Hypertens Suppl* 1986;4:S39-S41.
56. De Clerck F: Blood platelets in human essential hypertension. *Agents Actions* 1986;18:563-580.
57. Guicheney P, Baudouin-Legros M, Meyer P: Study of in vivo platelet activation in uncomplicated essential hypertension. *Life Sci* 1987;40:615-621.
58. Le Quan Sang KH, Laude D, Devynck MA: Platelet cytosolic free Ca<sup>2+</sup> concentration and serotonin (5-HT) content in essential hypertension. *J Hypertens* 1987;5:237-240.
59. Nityanand S, Tekwani BL, Chandra M, Shanker K, Singh BN: Kinetics of serotonin in platelets in essential hypertension. *Life Sci* 1990;46:367-372.
60. Brown CH 3rd, Leverett LB, Lewis CW, Alfrey CP Jr, Hellums JD: Morphological, biochemical, and functional changes in human platelets subjected to shear stress. *J Lab Clin Med* 1975;86:462-471.
61. Cattaneo M, Lombardi R, Bettega D, Lecchi A, Mannucci PM: Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine. *Arterioscler Thromb* 1993;13:393-397.
62. van den Berg EK, Schmitz JM, Benedict CR, Malloy CR, Willerson JT, Dehmer GJ: Transcardiac serotonin concentration is increased in selected patients with limiting angina and complex coronary lesion morphology. *Circulation* 1989;79:116-124.
63. Golino P, Piscione F, Benedict CR, Anderson HV, Cappelli-Bigazzi M, Indolfi C, Condorelli M, Chiariello M, Willerson JT: Local effect of serotonin released during coronary angioplasty. *N Engl J Med* 1994;330:523-528.
64. Cox JL: A perspective of postoperative atrial fibrillation in cardiac operations. *Ann Thorac Surg* 1993;56:405-409.
65. Aranki SF, Shaw DP, Adams DH, Rizzo RJ, Couper GS, VanderVliet M, Collins JJ Jr, Cohn LH, Burstin HR: Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources. *Circulation* 1996;94:390-397.
66. Bailly D, Vignau J, Lauth B, Racadot N, Beuscart R, Servant D, Parquet PJ: Platelet serotonin decrease in alcoholic patients. *Acta Psychiatr Scand* 1990;81:68-72.
67. Yamashita T, Murakawa Y, Sezaki K, Inoue M, Hayami N, Shuzui Y, Omata M: Circadian variation of paroxysmal atrial fibrillation. *Circulation* 1997;96:1537-1541.
68. Sopher SM, Hnatkova K, Waktare JE, Murgatroyd FD, Camm AJ, Malik M: Circadian variation in atrial fibrillation in patients with frequent paroxysms. *Pacing Clin Electrophysiol* 1998;21:2445-2449.
69. Malyszko J, Urano T, Knofler R, Taminato A, Yoshimi T, Takada Y, Takada A: Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes. *Thromb Res* 1994;75:569-576.
70. Meyerson LR, Strano R, Ocheret D: Diurnal concordance of human platelet serotonin content and plasma alpha-1-acid glycoprotein concentration. *Pharmacol Biochem Behav* 1989;32:1043-1047.
71. Modai I, Malmgren R, Wetterberg L, Eneroth P, Valevski A, Asberg M: Blood levels of melatonin, serotonin, cortisol, and prolactin in relation to the circadian rhythm of platelet serotonin uptake. *Psychiatry Res* 1992;43:161-166.
72. Klein I, Ojamaa K: Thyroid hormone and the cardiovascular system. *N Engl J Med* 2001;344:501-509.
73. Jais P, Haissaguerre M, Shah DC, Chouairi S, Gencel L, Hocini M, Clementy J: A focal source of atrial fibrillation treated by discrete radiofrequency ablation. *Circulation* 1997;95:572-576.
74. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Metayer P, Clementy J: Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. *N Engl J Med* 1998;339:659-666.
75. Chen SA, Tai CT, Yu WC, Chen YJ, Tsai CF, Hsieh MH, Chen CC, Prakash VS, Ding YA, Chang MS: Right atrial focal atrial fibrillation: Electrophysiologic characteristics and radiofrequency catheter ablation. *J Cardiovasc Electrophysiol* 1999;10:328-335.
76. Moe G, Abildskov J: Atrial fibrillation as a self sustaining arrhythmia independent of focal discharge. *Am Heart J* 1959;58:59-70.
77. Moe G: On the multiple wavelet hypothesis of atrial fibrillation. *Arch Int Pharmacodyn Ther* 1962;140:183-188.
78. Ramdat Misier A, Opthof T, van Hemel N, Defauw J, de Bakker J, Janse M, van Capelle F: Increased dispersion of "refractoriness" in patients with idiopathic atrial fibrillation. *J Am Coll Cardiol* 1992;19:1531-1535.
79. Wang J, Liu L, Feng J, Nattel S: Regional and functional factors determining induction and maintenance of atrial fibrillation. *Am J Physiol* 1996;271:H148-H158.
80. Daoud EG, Bogun F, Goyal R, Harvey M, Man KC, Strickberger SA, Morady F: Effect of atrial fibrillation on atrial refractoriness in humans. *Circulation* 1996;94:1600-1606.
81. Murgatroyd F, Camm A: Atrial arrhythmias. *Lancet* 1993;341:1317-1322.
82. Berlin J, Cannell M, Lederer W: Cellular origins of the transient inward current in cardiac myocytes: Role of fluctuation and waves of elevated intracellular calcium. *Circ Res* 1989;65:115-126.
83. Thandroyan FT, Morris AC, Hagler HK, Ziman B, Pai L, Willerson JT, Buja LM: Intracellular calcium transients and arrhythmia in isolated heart cells. *Circ Res* 1991;69:810-819.
84. January CT, Fozzard HA: Delayed afterdepolarizations in heart muscle: Mechanisms and relevance. *Pharmacol Rev* 1988;40:219-227.
85. Pino R, Cerbai E, Calamai G, Alajmo F, Borgioli A, Braconi L, Cassai M, Montesi GF, Mugelli A: Effect of 5-HT<sub>4</sub> receptor stimulation on the pacemaker current I(f) in human isolated atrial myocytes. *Cardiovasc Res* 1998;40:516-522.
86. Li GR, Feng J, Wang Z, Fermini B, Nattel S: Adrenergic modulation of ultrarapid delayed rectifier K<sup>+</sup> current in human atrial myocytes. *Circ Res* 1996;78:903-915.
87. Li GR, Feng J, Yue L, Carrier M, Nattel S: Evidence for two components of delayed rectifier K<sup>+</sup> current in human ventricular myocytes. *Circ Res* 1996;78:689-696.
88. Minamino T, Kitakaze M, Sato H, Asanuma H, Funaya H, Koretsune Y, Hori M: Plasma levels of nitrite/nitrate and platelet cGMP levels are decreased in patients with atrial fibrillation. *Arterioscler Thromb Vasc Biol* 1997;17:3191-3195.
89. Lip G, Lip P, Zaritis J, Watson R, Bareford D, Lowe G, Beevers D: Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. *Circulation* 1996;94:425-431.
90. Baumgartner H: The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. *Microvasc Res* 1973;5:167-179.
91. Lip G, Lowe G, Rumley A, Dunn F: Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. *Br Heart J* 1995;73:527-533.
92. Minamino T, Kitakaze M, Asanuma H, Ueda Y, Koretsune Y, Kuzuya T, Hori M: Plasma adenosine levels and platelet activation in patients with atrial fibrillation. *Am J Cardiol* 1999;83:194-198.
93. Lopez-Rodriguez ML, Benhamu B, Morcillo MJ, Murcia M, Viso A, Campillo M, Pardob L: 5-HT(4) receptor antagonists: Structure-affinity relationships and ligand-receptor interactions. *Curr Top Med Chem* 2002;2:625-641.